

BDR receives DCGI approval for launching Favipiravir in India

05 August 2020 | News

BDR Pharma has received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat mild to moderate patients with Covid-19 symptoms under the brand name BDFAVI.



Mumbai based BDR Pharmaceuticals recently announced the launch of Favipiravir for the treatment of COVID-19 patients in India. BDR Pharma has received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat mild to moderate patients with Covid-19 symptoms under the brand name BDFAVI. This approval comes after being one of the first companies to develop Remdesivir in the country and supply it on compassionate grounds to those suffering from the virus

BDR Pharma has persistently been at the forefront in supporting India's fight against COVID-19. In the short span of 4 months the company has launched 2 path-breaking drugs, to meet the increasing patients' needs and provide timely therapy options during the pandemic. Favipiravir, an antiviral drug used for the treatment of influenza in Japan since 2014, was approved by Drug Controller General of India for the treatment of mild to moderate cases of COVID-19 in India.

Favipiravir confirmed encouraging clinical evidence, with positive results in mild to moderate Covid-19 cases. BDR pharma has developed Favipiravir tablets in 200mg strengths with a strip of 10 tablets with the highest safety and manufacturing protocols in place to meet national and international demands.